Key Takeaways
- Price the instrument for what the consumable stream it secures is worth, not for the capital sale alone
- Record what a placement discount was supposed to buy, so the return can be measured against it
- Treat reimbursement as the outer ceiling, since a payer outside the negotiation sets what the customer can recover
- Price by site of care, because a hospital committee and a physician-owned surgery center buy on different terms
- Check which pricing regime a product sits in before assuming a discount stays local
- Review contract tiers against the volume actually delivered rather than the volume assumed
Intuitive Surgical sold $590.4 million of systems in a single quarter, and $1,518.8 million of the instruments and accessories those systems consume.
The capital sale is the one that gets negotiated, budgeted, and celebrated. The consumable is bought every procedure, for as long as the instrument stays in service, by a customer whose instrument only takes that consumable.
So a pricing strategy for medical device manufacturing has two jobs. It has to decide what the instrument is really selling, and it has to work out how much room exists once everyone outside the negotiation has had their say.
Why the Consumable Outearns the Instrument
A capital instrument is bought once, negotiated hard, and frequently placed at a price designed to get it into the hospital. The consumables it requires are bought for as long as the procedure is performed.
Intuitive Surgical publishes the split. In the quarter ended 30 September 2025 it reported instruments and accessories revenue of $1,518.8 million against systems revenue of $590.4 million, with service adding $395.9 million. The recurring stream ran roughly 2.6 times the capital one in the same three months.
Read the table downward and the negotiating logic inverts. That asymmetry is designed rather than accidental, because choosing a proprietary consumable interface over an open one is a pricing decision made years before the first sale.
The 6 Pricing Strategies Medical Device Manufacturers Run
The first strategy decides what the instrument is selling. The other five deal with the ceilings above it, each set by someone who is not in the room and each lower than the last.
The table names them. Each is then taken in turn, with what it looks like at a manufacturer already doing it.
Price the instrument for the stream it secures
A discount on the capital sale that secures the consumable stream can be the most profitable decision available. The same discount granted without securing it is margin given away.
That is why penetration pricing is legitimate in medtech and a dangerous habit anywhere the consumable stream does not follow. The difference is whether anyone wrote down what the placement was supposed to buy.
Bundling makes the same idea explicit. Selling the device, the consumables, and the service as one agreement stops asking the customer to value each piece separately and starts selling a working capability at a known cost.
Where Bundling Helps and Where It Fails
A bundle cheaper than its parts is a genuine commercial position and survives scrutiny. A bundle concealing a high consumable price does not, because unpicking bundles is what procurement teams are for. The trade is transparency, and it cuts both ways.
Price beneath the reimbursement ceiling
A device is worth what the payer will reimburse for the procedure it enables. That number is set by a third party outside the negotiation, and it caps everything below it.
iRhythm shows both halves. Management reported reaching 93 percent of all lives in the US covered for access to Zio, while expecting pricing to stay flat against the prior year within that coverage.
Coverage and price are separate fights, and winning one does not win the other. The company later reported reimbursement clarity improving as local coverage determinations were finalized, a regulatory decision that moved the ceiling more than any negotiation could.
Four functions reporting to different people jointly determine the realizable price, and only one of them is measured on it. Market access is a pricing function rather than a regulatory one, and evidence generation is a pricing investment.
Price by site of care
The consumable stream assumes a procedure, and the procedure has been moving. Work once done in a hospital operating room is increasingly done in an ambulatory surgery center, and the two buy on entirely different terms.
Stryker put a figure on the shift, saying that in its hip and knee business, procedures in ambulatory surgery centers are now pushing 20 percent against 5 percent before COVID. A quarter of that business changed venue inside a few years.
Pricing the same device identically into all four is the common error, and it usually shows up as a hospital contract price quietly becoming the reference for a segment that never earned it. A target pricing strategy set per channel rather than per product is the correction.
One thing that is not a pricing input, though it gets treated as one: clearance through the 510(k) route establishes substantial equivalence to something already on the market. That is a statement about safety and effectiveness rather than superiority, so a value argument has to rest on evidence the manufacturer generates itself.
Check which pricing regime applies before discounting
This is where most medtech pricing conversations go wrong. Average sales price gets discussed as though it governed devices, and it does not.
The regulation applies to drugs and biological products payable under Medicare Part B, reported by manufacturers against a National Drug Code. Devices do not carry one, and there is no device equivalent of that regime.
There is a genuine device-specific mechanism, and it is narrower than the drug regime it gets confused with. Transitional pass-through payment is priced off the hospital’s acquisition cost, runs for a limited period after clearance, and applies only where device cost is large relative to the procedure payment.
That narrowness has a direct consequence. Where a pass-through applies, the acquisition cost a manufacturer negotiates becomes the basis for the payment, so a concession gives up margin on the account and enters a formula as a lower number.
Build contract tiers on committed volume
Reimbursement sets the outer limit and the contract decides how much of it a manufacturer keeps. That contract is frequently held not with the hospital using the device but with a group purchasing organization negotiating for many.
Specific terms are private and nobody publishes what they conceded. The structure is consistent enough to plan against, and five terms carry most of the weight:
- Committed against uncommitted tiers: a lower price for a share-of-supply commitment is a different agreement from one offered against an expectation
- The tier the member actually reaches: a tier priced for volume the member never achieves is a discount given for nothing
- Administrative fees: the fee paid to the organization is part of the realized price and belongs in the margin calculation
- What the agreement forecloses: a national agreement can make it hard to price differently to a member whose economics genuinely differ
- Price protection across the term: a cap agreed in year one is a commitment through year five, conceded easily in a tender and hard to live with after
The last deserves attention it rarely gets, because a cap removes the ability to reprice at exactly the moment repricing is warranted. Where one is unavoidable, an adjustment mechanism tied to something published moves the ceiling with a number neither party controls.
The Cheapest Fix Available
Record the volume assumption alongside the price at the moment a tier is agreed. By renewal, the cost of never reviewing it is invisible because nobody wrote down what the tier assumed, and the conversation becomes two parties recalling a meeting differently. Where the record exists, it starts from evidence instead.
Plan for tenders and reference pricing
A group purchasing agreement concentrates buying power within a market. National procurement concentrates it across one, and the effect on price is larger by an order of magnitude.
Medtronic described the position plainly, reporting low single-digit growth in China while navigating ongoing but manageable volume-based procurement in a few businesses, with growth mid-single digit excluding it. The gap between those two numbers is the mechanism working.
The bottom row reaches across a portfolio. A country pricing by reference to a basket of comparable markets imports whatever the lowest of them negotiated, which makes the order of market entry worth more than most of the negotiations inside it.
A discount granted to win a small market early can cost far more than it earns once larger markets anchor to it, and by then the number is public and permanent.
Holding Instruments and Consumables in One Structure
Each strategy is manageable alone. A medtech business runs all six at once, with a capital line and a consumable line whose prices depend on each other, several sites of care, national agreements, and export markets that reference one another.
Three capabilities decide whether that holds together:
- The instrument price knows what it bought: a placement discount granted to secure a consumable stream should be recorded as exactly that
- Every concession is visible before it spreads: a discount that becomes a reference reaches beyond the account that received it
- Tiers are reviewed against achieved volume: a tier is a price granted for a promise, and nobody checks the promise unless the system surfaces it
Conclusion
Four functions decide what a medical device actually earns. Clinical affairs decides whether a coverage argument can be made. Market access decides the ceiling. Commercial decides how much of it is captured. Finance decides whether anyone notices when a concession spreads.
Only the third of those has pricing in its title, and it is the one with the least room to move. The other three set the boundaries it works inside, usually months or years earlier, and usually without describing the decision as a pricing one.
Which is why the useful question in this industry is rarely what to charge. It is who already decided, and whether anybody told the people holding the price list.
If those four answers currently live in four different places, that is the gap worth closing first. Book a demo and bring one contract.
Frequently Asked Questions
What are the main pricing strategies in medical device manufacturing?
Six work together: pricing the instrument for the consumable stream it secures, pricing beneath the reimbursement ceiling, pricing by site of care, checking which regime applies before discounting, building tiers on committed volume, and planning for tenders and reference pricing.
Why is the consumable worth more than the instrument in medtech?
Because the instrument is bought once under competition and the consumable is bought every procedure by a customer whose instrument only takes that consumable. Intuitive Surgical reported instruments and accessories revenue of $1,518.8 million against systems revenue of $590.4 million in the quarter ended September 2025.
Should the same device be priced identically to a hospital and an ambulatory surgery center?
Generally not, because the buyer, the decision process, and the reimbursement all differ. Stryker reports hip and knee procedures in ambulatory centers pushing 20 percent against 5 percent before COVID, so the segment is now large enough that a hospital-derived price applied to it is a real cost.
How does reimbursement limit what a device can be priced at?
It sets what the customer can recover for the procedure the device enables, which caps what they can pay for it. iRhythm reached 93 percent of US lives covered while expecting pricing flat year over year, which shows coverage and price are separate fights.
Does average sales price apply to medical devices?
No. It applies to drugs and biological products payable under Medicare Part B, reported against a National Drug Code, and devices do not carry one. The device-specific mechanism is transitional pass-through payment, which is narrower and time-limited.
How should a manufacturer approach a national tender market?
As a structural feature rather than an event. Medtronic described navigating ongoing volume-based procurement in China with growth mid-single digit excluding it, which is a business planning around the mechanism rather than reacting to it.
As an experienced pricing solutions partner to some of the biggest names in global business, Vistaar offers a range of services to help our customers reach their maximum potential. Talk to us to see how we can help you create a more profitable future.
